Clinical Implications (Lung cancer): METTL3 inhibition is best suited for tumors demonstrating METTL3-dependent, eIF3h-facilitated translational activation and IGF2BP-mediated stabilization of MYC or HIF-1α pathways. Here, HIF1A is linked to lung carcinoma.